Breaking Down Hebei Jianxin Chemical Co., Ltd. Financial Health: Key Insights for Investors

Investors probing Hebei Jianxin Chemical Co., Ltd. (300107.SZ) will find a company with sharply falling top-line momentum-Q1 2025 revenue of CNY 117.95 million (-23.3% year-over-year) and a trailing twelve-month revenue of CNY 521.86 million (a 25.35% decline versus the prior TTM)-paired with thin profitability (nine-month EPS of CNY 0.001 and net profit margin around 2.3%), heavy leverage (debt-to-equity ~1.76 with total liabilities of CNY 2.19 billion), tight liquidity (current ratio ~1.2, quick ratio ~0.9, cash ratio ~0.5) and negative free cash flow (quarter FCF margin -23.15%, FCF -CNY 27.8 million) even as management invests CNY 130.1 million in capex and raises CNY 130 million for expansion-yet the market prices the stock at a premium (market cap CNY 3.78 billion, P/S 7.39, TTM P/E 324.68), creating a tension between valuation and fundamentals that warrants a closer look-read on for a detailed breakdown of revenue trends, profitability drivers, capital structure, liquidity, valuation and growth opportunities.

Hebei Jianxin Chemical Co., Ltd. (300107.SZ) - Revenue Analysis

Hebei Jianxin Chemical's top-line trajectory has been contracting for three consecutive years, with pronounced weakness persisting into the first quarter of 2025. Key headline figures illustrate the pace and scale of the decline and provide context for valuation metrics and productivity measures.

• Q1 2025 revenue: CNY 117.95 million (down 23.3% YoY vs. CNY 154.03 million in Q1 2024).
• TTM revenue as of 30-Jun-2025: CNY 521.86 million (down 25.35% vs. prior TTM of CNY 698.21 million).
• FY 2024 revenue: CNY 605.38 million (down 8.03% vs. CNY 658.21 million in 2023).
• Revenue per employee (2025): ~CNY 567,850 based on 919 employees.
• Market capitalization (12-Dec-2025): CNY 3.78 billion; P/S ratio: 7.39.

The persistent negative revenue growth - 25.35% in the trailing 12 months to mid‑2025, 8.03% in 2024 and 11.35% in 2023 - compresses margin leverage and raises sensitivity to fixed costs and working capital dynamics. For historical context and company background, see Hebei Jianxin Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money.

Hebei Jianxin Chemical Co., Ltd. (300107.SZ) Profitability Metrics

Hebei Jianxin Chemical's recent results show contraction in core profitability and cash-generation despite continued capital investment. Key headline figures:

• Q1 2025 net income: CNY 1.61 million (vs. CNY 8.13 million in Q1 2024)
• Net profit margin (9 months ended Sep 30, 2025): ~2.3% (vs. 3.2% same period 2024)
• EPS (9 months ended Sep 30, 2025): CNY 0.001 (vs. CNY 0.003 same period 2024)
• ROE (9 months ended Sep 30, 2025): 0.77% (vs. 0.80% same period 2024)
• Operating cash flow (9 months ended Sep 30, 2025): CNY 44.2 million
• Capital expenditures (9 months ended Sep 30, 2025): CNY 130.1 million
• Free cash flow (quarter ended Jun 30, 2025): negative CNY 27.8 million; free cash flow margin -23.15%

Contextual points for investors:

• Profitability compression: lower net margin and EPS reflect either margin pressure or mix/volume declines versus the prior year.
• Cash-flow profile: positive operating cash flow (CNY 44.2M) is offset by heavy capex (CNY 130.1M) producing negative free cash flow in Q2 and material outflows over nine months.
• Capital allocation risk: sustained high capex relative to operating cash raises liquidity and returns questions until investments translate to higher margins or volumes.
• Shareholder returns: ROE near 0.77% signals very low equity returns in 2025 YTD compared with prior year.

For broader corporate context and strategic positioning, see: Mission Statement, Vision, & Core Values (2026) of Hebei Jianxin Chemical Co., Ltd.

Hebei Jianxin Chemical Co., Ltd. (300107.SZ) - Debt vs. Equity Structure

• Total assets: CNY 3.43 billion (as of June 30, 2025)
• Total equity: CNY 1.24 billion (as of June 30, 2025)
• Total liabilities: CNY 2.19 billion (as of June 30, 2025)
• Debt-to-equity ratio: ~1.76 (2.19 / 1.24)
• Equity ratio: ~36.1% (1.24 / 3.43)

• The balance-sheet mix (36.1% equity, 63.9% liabilities) points to a leveraged capital structure where creditors fund a majority of assets.
• Debt-to-equity at ~1.76 is moderate-to-high for a chemical manufacturer and indicates interest-rate and refinancing sensitivity.
• Material capital expenditure (CNY 130.1M) combined with CNY 130M of external financing for the Cangzhou subsidiary signals a growth-oriented capital allocation strategy.

Hebei Jianxin Chemical Co., Ltd. (300107.SZ) - Liquidity and Solvency

• Short‑term coverage: current ratio 1.2 suggests overall coverage but quick ratio 0.9 signals potential difficulty meeting obligations without liquidating inventory.
• Cash cushion: cash ratio 0.5 indicates only half of current liabilities could be covered by cash and equivalents.
• Investment vs. cash generation: operating cash flow of CNY 44.2m vs. capex CNY 130.1m over nine months reflects heavy investment activity driving negative free cash flow (CNY 27.8m in Q2, free cash flow margin -23.15%).
• Financing pressure: recurring negative FCF and limited cash reserves may necessitate external financing or working capital management adjustments to fund growth initiatives.

Hebei Jianxin Chemical Co., Ltd. (300107.SZ) - Valuation Analysis

• Trailing twelve months P/E: 324.68 (as of 2025-12-12)
• Price-to-Sales (P/S): 7.39 (as of 2025-12-12)
• Market capitalization: CNY 3.78 billion (as of 2025-12-12)
• Share price: CNY 6.72 (as of 2025-12-12)
• Earnings per share (EPS) for nine months ended 2025-09-30: CNY 0.001

• High P/E driven by very low EPS - even small earnings changes will swing the ratio materially.
• P/S of 7.39 implies expectations of strong future margin expansion or growth; absent that, downside risk increases.
• Market cap of CNY 3.78 billion and share price of CNY 6.72 make the stock sensitive to liquidity and sentiment shifts.
• Current nine-month EPS of CNY 0.001 signals limited near-term earnings support for the elevated multiple.

Hebei Jianxin Chemical Co., Ltd. (300107.SZ) Risk Factors

Key financial signals point to material risks for Hebei Jianxin Chemical Co., Ltd. (300107.SZ). The company has experienced consecutive revenue declines, a compressing net profit margin, elevated leverage and negative free cash flow - factors that raise solvency and liquidity concerns and increase sensitivity to macroeconomic and interest-rate movements. See also: Hebei Jianxin Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

• Revenue decline trend: three-year contraction with -11.35% (2023), -8.03% (2024), and -25.35% (2025).
• Profitability compression: net profit margin fell from 3.2% in 2024 to 2.3% in 2025, signaling lower operating efficiency or margin pressure.
• High financial leverage: debt-to-equity ratio ≈ 1.76 as of June 30, 2025, indicating significant reliance on borrowed funds.
• Negative operating liquidity: free cash flow margin of -23.15% for the quarter ending June 30, 2025, suggesting cash outflows exceed operating cash generation.
• Exposure to interest-rate and refinancing risk due to reliance on debt financing and sizable capital expenditures.

• Investor implications: elevated default probability if adverse conditions persist given weak cash conversion and high debt load.
• Monitoring priorities: sequential revenue trends, margin recovery, cash flow improvement, debt maturities and refinancing terms, and capex vs. free cash flow alignment.

Hebei Jianxin Chemical Co., Ltd. (300107.SZ) - Growth Opportunities

• Market leadership in dye intermediates and thermal paper color formers (notably ODB-1 and ODB-2) supports pricing power and stable margins.
• Global export network supplying Europe, the U.S., Japan, and Korea diversifies demand risk and enables premium pricing in developed markets.
• R&D pipeline backed by five invention patents and eleven utility model patents fosters product differentiation and incremental margin improvement.
• Strategic partnerships targeting sustainable chemical production aim to cut operating costs and improve ESG credentials.
• Focus on high-performance polymers (e.g., polysulfonamide fibers) positions the company to capture higher-growth end-markets such as advanced textiles, filtration, and engineering plastics.

• Export expansion: leveraging existing distribution in Europe/US/Asia to increase international sales share from ~40% to 50% within 3 years, targeting higher-margin industrial customers.
• R&D commercialization: converting patented formulations into specialty grades for filtration, medical disposables, and electronics, where margins exceed commodity dye levels.
• Operational efficiency: implementing sustainable production techniques projected to cut unit production costs by ~20% over three years, improving gross margins materially.
• Product mix upgrade: shifting sales mix toward high-performance polymers and specialty intermediates to raise blended gross margin and reduce cyclicality tied to commodity dyes.

• Rate of export revenue growth (target +25% over 3 years)
• R&D conversion: number of patent-backed products commercialized annually (goal: 2-3 new SKUs/year)
• Cost reduction progress vs. baseline (target cumulative ~20% in 3 years)
• Revenue share from high-performance polymer segment (target increase from current level to >20% within 3 years)